REMoDL-B

From Ganfyd

Jump to: navigation, search
Name of Trial: REMoDL-B
Full Name
Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
Type of Trial
RCT
Studied
On-going. Studying addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in treatment of Diffuse Large B-cell Lymphoma (DLBCL).
Primary Outcome
Progression-free survival
Other Outcomes
Overall survival, Event-free survival, Disease-free survival, Time to progression, Response duration, Complete and overall response rates, Evaluation of toxicity, Quality of life and assessment of peripheral neuropathy.
Summary
On-going.
Criticisms and Limitations
Study not completed yet.
Clinical Trial Websites
Relevant Clinical Literature

On-going...

Personal tools